Measuring and defining screening benefit in a new era of cancer early detection.
A proposed framework helps researchers fairly evaluate blood tests that screen for multiple cancers at once, essential as these tests enter clinical use.
This JNCI article proposes a framework for measuring cancer screening benefit as multi-cancer early detection (MCED) tests enter clinical use. The authors address how traditional screening endpoints need adaptation for MCED evaluation, directly relevant to ongoing clinical trials of blood-based cancer screening.
What the study was
- Study design
- Perspective/Framework
- Population
- General screening population
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Journal of the National Cancer Institute
Why it surfaced
Framework paper from leading screening researchers in JNCI addressing how to evaluate MCED tests. Directly relevant to liquid biopsy and early detection pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.